Jade Biosciences, Inc. (JBIO) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Jade Biosciences, Inc. is a clinical-stage biopharmaceutical company developing biologic therapies for autoimmune diseases. The company operates as a single reportable segment focused on three product candidates: JADE101 (anti-APRIL for IgA nephropathy), JADE201 (anti-BAFF-R for autoimmune disorders), and JADE301 (undisclosed target). The company is an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(40,368) | $(38,169) |
| Operating Expenses | $43,445 | $23,384 |
| Research & Development (R&D) | $36,053 | $20,023 |
| General & Administrative (G&A) | $7,392 | $3,361 |
| Interest Income | $3,102 | $615 |
| Cash & Cash Equivalents (End of Period) | $55,085 | $49,929 |
| Investments | $256,210 | N/A |
| Total Liquidity (Cash + Investments) | $311,295 | N/A |
| Net Cash Used in Operating Activities | $(24,081) | $(18,757) |
| Accumulated Deficit | $(214,757) | $(85,148) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $20.1 million (86%) year-over-year, driven primarily by a $16.0 million increase in R&D expenses.
- R&D Spend Allocation: R&D costs for JADE101 increased by $5.7 million, and JADE301 costs surged by $5.2 million. JADE201 costs decreased by $2.3 million.
- Stock-Based Compensation: Total stock-based compensation expense increased to $7.4 million from $2.4 million, largely due to the recognition of the Parade Warrant Obligation ($2.7 million) and increased option grants.
- Convertible Notes: Unlike Q1 2025, which included a $15.4 million non-cash loss from the change in fair value of convertible notes, Q1 2026 had no such charge as the notes converted to equity in April 2025.
- Interest Income: Interest income increased significantly to $3.1 million from $0.6 million due to higher investment balances and interest rates.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and investments ($311.3 million) to fund operations for at least 12 months from the filing date.
- Clinical Milestones:
- JADE101: Phase 1 trial in healthy volunteers initiated in August 2025; interim data expected in Q2 2026. Phase 2 in IgAN patients planned for Q2 2026.
- JADE201: Phase 1 trial in rheumatoid arthritis patients planned for Q2 2026.
- JADE301: Phase 1 trial expected in the first half of 2027.
- Capital Markets Activity: On May 7, 2026, the company entered into an Open Market Sale Agreement ("At-the-Market" offering) with Jefferies LLC to sell up to $200.0 million of common stock. No shares have been sold to date.
- Risks: Key risks include the uncertainty of clinical trial outcomes, dependence on third-party manufacturers (including potential impacts of the U.S. BIOSECURE Act on Chinese CMOs), reliance on Paragon Therapeutics for IP and discovery, and the need for substantial additional capital to achieve profitability.
Investor Verification Checklist
- Verify the status and enrollment progress of the JADE101 Phase 1 trial in New Zealand and the timeline for Q2 2026 data readouts.
- Confirm the impact of the U.S. BIOSECURE Act on the company's reliance on WuXi Biologics and other foreign CMOs for manufacturing.
- Monitor the execution of the new $200 million ATM facility and any dilution from future sales.
- Review the specific terms of the Paragon Option Agreement regarding milestone payments and royalty obligations for JADE101, JADE201, and JADE301.
- Assess the burn rate relative to the $311 million liquidity position to validate the 12-month runway assertion.